Skip to main content
SpringerLink
Log in

Personalized Medicine in NF1

  • Chapter
  • First Online:
Neurofibromatosis Type 1

  • 1505 Accesses

Abstract

Anticipatory guidance is the application of general guidelines for care of individuals with health conditions (e.g., asthma) once a diagnosis has been established. This activity is also applied to myriad genetic conditions such as Down syndrome, cystic fibrosis, and neurofibromatosis type 1. As an extension of this care, personalized medicine is a concept that holds great promise for the individualization of anticipatory guidance provided to a population within a diagnostic category. We are on the verge of applying the principles of personalized medicine to NF1. However, to fully implement such programs, we must integrate evidence-based medicine (outcomes research), biomarkers, and clinical decision support into comprehensive health-care plans.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Balas E, Boren S (2000) Managing clinical knowledge for health care improvement. In: Bemmel J, McCray AT (eds) Yearbook of medical informatics 2000: patient-centered systems. Schattauer, Stuttgart, pp 65–70

    Google Scholar 

  • Chabernauda C, Mennes M, Kardelb P, Gaillardc W, Kalbfleischd M, VanMeter J, Packer R, Milham M, Castellanos F, Acosta M (2012) Lovastatin regulates brain spontaneous low-frequency brain activity in neurofibromatosis type 1. Neurosci Lett 515:28–33

    Article  Google Scholar 

  • De Raedt T, Brems H, Wolkenstein P, Vidaud D, Pilotti S, Perrone F, Mautner V, Frahm S, Sciot R, Legius E (2003) Elevated risk for MPNST in NF1 microdeletion patients. Am J Hum Genet 72:1288–1292

    Article  PubMed  Google Scholar 

  • Ginsburg G, Willard H (2009) Genomic and personalized medicine: foundations and applications. Transl Res 154:277–287

    Article  PubMed  Google Scholar 

  • KayesLM BW, Riccardi VM, Bennett R, Ehrlich P, Rubenstein A, Stephens K (1994) Deletions spanning the neurofibromatosis 1 gene: identification and phenotype of five patients. Am J Hum Genet 54:424–436

    Google Scholar 

  • Krab L, Aarsen F, de Goede-Bolder A, Catsman-Berrevoets C, Arts W, Moll H, Elgersma Y (2008) Impact of neurofibromatosis type 1 on school performance. J Child Neurol 23:1002–1010

    PubMed  Google Scholar 

  • Mautner V-F, Asuagbor F, Dombi E, Funsterer C, Kluwe L, Wenzel R, Widemann B, Friedman J (2008) Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1. Neuro Oncol 10:593–598

    Article  PubMed  Google Scholar 

  • Mautner VF, Kluwe L, Friedrich RE, Roehl AC, Bammert S, Högel J, Spöri H, Cooper DN, Kehrer-Sawatzki H (2010) Clinical characterisation of 29 neurofibromatosis type-1 patients with molecularly ascertained 1.4 Mb type-1 NF1 deletions. J Med Genet 47:623–630

    Article  PubMed  CAS  Google Scholar 

  • Osheroff J, Teich J, Middleton B, Steen E, Wright A, Detmer D (2007) A roadmap for national action on clinical decision support. J Am Med Inform Assoc 14:141–145

    Article  PubMed  Google Scholar 

  • Pasmant E, Sabbagh A, Spurlock G, Laurendeau I, Grillo E, Hamel MJ, Martin L, Barbarot S, Leheup B, Rodriguez D, Lacombe D, Dollfus H, Pasquier L, Isidor B, Ferkal S, Soulier J, Sanson M, Dieux-Coeslier A, Bièche I, Parfait B, Vidaud M, Wolkenstein P, Upadhyaya M, Vidaud D, Members of the NF France Network (2010) NF1 microdeletions in neurofibromatosis type 1: from genotype to phenotype. Hum Mutat 31:E1506–E1518

    Article  PubMed  CAS  Google Scholar 

  • Plotkin S, Bredella M, Cai W, Kassarjian A, Harris G, Esparza S, Merker V, Munn L, Muzikansky A, Askenazi M, Nguyen R, Wenzel R, Mautner V (2012) Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosis. PLoS One 7:e35711

    Article  PubMed  CAS  Google Scholar 

  • Poon A, Hamid Q (2012) Personalized medicine for asthma: are we there yet? Ann Thorac Med 7:55–56

    Article  PubMed  Google Scholar 

  • Rasmussen S, Yang Q, Friedman J (2001) Mortality in neurofibromatosis 1: an analysis using U.S. death certificates. Am J Hum Genet 68:1110–1118

    Article  PubMed  CAS  Google Scholar 

  • Rosenfeld A, Listernick R, Charrow J, Goldman S (2010) Neurofibromatosis type 1 and high-grade tumors of the central nervous system. Childs Nerv Syst 25:663–667

    Article  Google Scholar 

  • Sbidian E, Wolkenstein P, Valeyrie-Allanore L, Rodriguez D, Hadj-Rabia S, Ferkal S, Lacour J-P, Leonard J-C, Taillandier L, Sportich S, Berbis P, Bastuji-Garin S, Members of the NF France Network (2010) NF-1Score: a prediction score for internal neurofibromas in neurofibromatosis-1. J Invest Derm 130:2173–2178

    Article  PubMed  CAS  Google Scholar 

  • Sharif S, Moran A, Huson S, Iddenden R, Shenton A, Howard E, Evans D (2007) Women with neurofibromatosis 1 are at a moderately increased risk of developing breast cancer and should be considered for early screening. J Med Genet 44:481–484

    Article  PubMed  CAS  Google Scholar 

  • Stevenson D, Viskochil D, Rope A, Carey J (2006) Clinical and molecular aspects of an informative family with neurofibromatosis type 1 and Noonan phenotype. Clin Genet 69:246–253

    Article  PubMed  CAS  Google Scholar 

  • Upadhyaya M, Huson SM, Davies M, Thomas N, Chuzhanova N, Giovannini S, Evans DG, Howard E, Kerr B, Griffiths S, Consoli C, Side L, Adams D, Pierpont M, Hachen R, Barnicoat A, Li H, Wallace P, Van Biervliet JP, Stevenson D, Viskochil D, Baralle D, Haan E, Riccardi V, Turnpenny P, Lazaro C, Messiaen L (2007) An absence of cutaneous neurofibromas associated with a 3-bp inframe deletion in exon 17 of the NF1 gene (c.2970–2972 delAAT): evidence of a clinically significant NF1 genotype-phenotype correlation. Am J Hum Genet 80:140–151

    Article  PubMed  CAS  Google Scholar 

  • Viskochil D (2010) Neurofibromatosis Type 1. In: Allanson J, Cassidy S (eds) Management of genetic syndromes. Wiley, New York

    Google Scholar 

  • Walker L, Thompson D, Easton D, Ponder B, Ponder M, Frayling I, Baralle D (2006) A prospective study of neurofibromatosis type 1 cancer incidence in the UK. Br J Cancer 95:233–238

    Article  PubMed  CAS  Google Scholar 

  • Willard HF, Ginsburg GS (eds) (2009) Genomic and personalized medicine. vols. 1 and 2. Academic, Amsterdam

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Medical Genetics, Department of Pediatrics, University of Utah, Salt Lake City, UT, USA

    David Viskochil

Authors
  1. David Viskochil
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David Viskochil .

Editor information

Editors and Affiliations

  1. School of Medicine, Institute of Medical Genetics, Cardiff University, Heath Park Campus, Cardiff, 144XN, United Kingdom

    Meena Upadhyaya

  2. School of Medicine, Institute of Medical Genetics, Cardiff University, Heath Park, Cardiff, CF14 4XN, United Kingdom

    David N. Cooper

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Viskochil, D. (2012). Personalized Medicine in NF1. In: Upadhyaya, M., Cooper, D. (eds) Neurofibromatosis Type 1. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-32864-0_43

Download citation

Publish with us

Policies and ethics

Search

Navigation